Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (July 2025)
27 slides from Adalta's investor presentation, Jul 30, 2025
Slide 1: Commercialising Cellular Immunotherapies East to West
For personal use only COMMERCIALISING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | JULY 2025 AdAlta Limited (ASX:1AD) | Investor Presentation | July 2025 | 1
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. For personal use only This presentation is
Slide 3: AdAlta: Next Generation Cell & Protein Therapeutics
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS “East to West” cellular immunotherapy strategy for growth: AdCella In-license next generation clinical stage assets from Asia, establish For personal use only Western manufacturing and generate clinical data for on-licensing AdAlta is a clinical st
Slide 4: East to West Strategy Central to AdAlta's Growth
For personal use only “EAST TO WEST” STRATEGY CENTRAL TO ADALTA’S GROWTH AdCella Pty Ltd, an AdAlta company AdAlta Limited (ASX:1AD) | Investor Presentation | July 2025 | 44
Slide 5: East to West Strategy Overview
“EAST TO WEST” STRATEGY OVERVIEW Substantial value inflection potential by bringing “Eastern” cellular AdCella has clear For personal use only immunotherapy innovations to “Western” regulated markets aspirational growth targets for its Exclusive focus on T cell therapies for solid cancers targets le
Slide 6: Rationale for Our Strategy
RATIONALE FOR OUR STRATEGY Market opportunity Competitive advantage Exclusive access to first assets For personal use only Cancers that are solid • Networks: Asia's rich innovation, Exclusive access to initial three assets from tumours and remain Australia's clinical and manufacturing pipeline of 10
Slide 7: Becoming a Valuation Multiplier for Asian Partners
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS For personal use only 3 In-license market leading 3 assets from Asia (“East”): 1 Low acquisition cost. By financing to next inflection On-licensing: point AdAlta acquires a Establish global share of the asset at exit manufacturing network and on-lic
Slide 8: Value at Exit: Phase I CAR-T Licensing Transactions
VALUE AT EXIT: PHASE I CAR-T LICENSING TRANSACTIONS Total Upfront Date Drug(s) Licensor Licensee Deal stage Lead indications value (US$m) (US$m) For personal use only MAGE-A4 targeting TCR T Phase 2 May-24 Head & neck cancer 665 85 cell therapy (ongoing; global) DLL3 targeting autologous Phase 1 Nov
Slide 9: Progress and Potential
PROGRESS AND POTENTIAL Asset acquisition stream – exclusive access secured Australian clinical • Technical and on-site diligence, development planning complete We are here trial data facilitates • On track for first asset license Q3 2025 pivotal studies, For personal use only today • Discussions ope
Slide 10: Asset #1: First-in-Class Armoured X-CAR-T
ASSET #1: FIRST-IN-CLASS ARMOURED X-CAR-T Product #1 Advanced, solid cancer Armoured-X-CAR-T patient: sustained response For personal use only What is the Anti-PD1 secreting CAR-T manufactured using 30h virus to armored-CAR-T product? free process Which cancers Lung, mesothelioma, ovarian, cervical,
Slide 11: Asset #2: First-in-Class Y-CAR-T
ASSET #2: FIRST-IN-CLASS Y-CAR-T Product #2 Pancreatic tumor B4T2-001 cleared bypancreatic CAR-T Y-CAR-T in re-challenge model tumor re-challenge • We conducted a tumor re-challenge study in which Y-CAR-T mice were re-engraftment with tumor cells after having experienced a complete response to a Unt
Slide 12: AD-214: A New Approach to Fibrosis
For personal use only AD-214: A NEW APPROACH TO FIBROSIS AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | 12 July 2025 | 12
Slide 13: Monetising Fibrosis Disease Drug Candidate AD-214
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214 Investment to date has built strong value proposition Key Priority: Seek out-licensing or third-party investment to For personal use only unlock next level of value First in class molecule targeting established mode ✓ Competitively positioned as only
Slide 14: Underserved and Large Fibrotic Disease Market
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET IPF market is underserved today Many other fibrosis market opportunities2 For personal use only • Poor efficacy: Existing therapies slow but do not halt progression and do not significantly extend life expectancy • Side effects: Their side effects result
Slide 15: Pharma Companies Value IPF/Fibrosis Assets
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS Upfront payment to Contingent Clinical Phase at Date Licensor/target Licensee/acquirer Transaction licensor milestones transaction For personal use only Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisition US$45m Not disclosed 2a complete Nov-19 Acq
Slide 16: WD-34 i-body: A Potential Breakthrough in Malaria
For personal use only WD-34 I-BODY: A POTENTIAL BREAKTHROUGH IN MALARIA AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | 16 July 2025 | 16
Slide 17: World First Pan-Species High Potency Anti-Malarial
WORLD FIRST PAN-SPECIES HIGH POTENCY ANTI-MALARIAL WD-34 i-body has potential to transform malaria treatment Strategy: seeking non-dilutive and commercial For personal use only ✓ 247 million cases, 619,000 deaths in 20211 partners to advance outside AdAlta Malaria remains a ✓ Re-emerging in US and E
Slide 18: Corporate Information
For personal use only CORPORATE INFORMATION AdAlta Limited (ASX:1AD) | Investor Presentation | 18 July 2025 | 18
Slide 19: Corporate Snapshot
CORPORATE SNAPSHOT AdAlta Limited Specialist in next-generation cell and protein For personal use only therapeutics for fatal diseases Code ASX:1AD Market Capitalisation $2.2m Exclusive position on three "East-to-West" cell Enterprise Value $0.9m therapy assets, with team and execution Cash (30 June
Slide 20: Experienced Team with Global Reach
EXPERIENCED TEAM WITH GLOBAL REACH Board Executive “East-to-West” Strategy AD-214: Fibrosis For personal use only Paul MacLeman, DVM Angus Tester, PhD Kevin Lynch TBA - engaged Chair Senior Director Operations Consultant CMO Consultant CMO Prof Andrew Wilks Joseph Tyler VC Advisor Consultant CMC Exp
Slide 21: Transaction-Based Growth Strategy Is Being Delivered
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED For personal use only “East to West” cellular Exclusive position on first three Experienced team and accessible immunotherapy growth strategy assets for the “East to West” clinical global network ready to execute a positioned for growth leveraging
Slide 22: For More Information Please Contact
For personal use only FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 T.OLDHAM@ADALTA.COM.AU IR@ADALTA.COM.AU WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | Investor Presentation | July 2025 | 22
Slide 23: The Market Opportunity
THE MARKET OPPORTUNITY T cell solid cancer therapy: the next frontier for cellular immunotherapy For personal use only In 2024, FDA approved two What is T-cell therapy? 6 FDA-approved CAR-T T cell therapies for solid therapies since 2017 cancer (melanoma, Involves re-engineering and transformed bloo
Slide 24: Accessing Quality Assets from Asia
ACCESSING QUALITY ASSETS FROM ASIA Quality Asia cellular Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western immunotherapy pipeline, experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty For personal use only
Slide 25: Leveraging AdCella's Competitive Advantages
LEVERAGING ADCELLA’S COMPETITIVE ADVANTAGES Process: asset sourcing discipline Value: capital-light, risk managed For personal use only • T cell therapies for solid cancers • AdAlta managed; JV/asset financed • Differentiated, multi-functional • Defined investment in clinically product design derisk
Slide 26: First-in-Class Armoured X-CAR-T
1. FIRST-IN-CLASS ARMOURED X-CAR-T Product design and differentiation Advanced, solid cancer patient: • First aPD1 armored X-CAR-T: targets known resistance mechanism enhancing potency of CAR-T, bystander T cells sustained response to armored-CAR-T For personal use only • Non-viral vector transducti
Slide 27: First-in-Class Y-CAR-T
2. FIRST-IN-CLASS Y-CAR-T Product design and differentiation • Novel target engages tumour and subset of immune cells to support engraftment, proliferation and persistence Complete resolution of For personal use only • Can be multi-dosed with low/no lymphodepletion and administered IV and IP maligna